Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Operating Leases (2019 - 2025)

Sonoma Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $509000.0 for Q4 2025.

  • For Q4 2025, Operating Leases rose 327.73% year-over-year to $509000.0; the TTM value through Dec 2025 reached $509000.0, up 327.73%, while the annual FY2025 figure was $27000.0, 68.97% down from the prior year.
  • Operating Leases for Q4 2025 was $509000.0 at Sonoma Pharmaceuticals, up from $479000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $722000.0 in Q2 2021 and troughed at $27000.0 in Q1 2025.
  • A 5-year average of $331700.0 and a median of $345500.0 in 2023 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: tumbled 82.77% in 2024 and later skyrocketed 621.31% in 2025.
  • Year by year, Operating Leases stood at $362000.0 in 2021, then plummeted by 46.13% to $195000.0 in 2022, then skyrocketed by 74.87% to $341000.0 in 2023, then crashed by 65.1% to $119000.0 in 2024, then soared by 327.73% to $509000.0 in 2025.
  • Business Quant data shows Operating Leases for SNOA at $509000.0 in Q4 2025, $479000.0 in Q3 2025, and $440000.0 in Q2 2025.